Company Overview
| Stock Name | Yunkang Group |
|---|---|
| Stock Code | 02325 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國的一家醫學運營服務提供商,為醫療機構提供全套診斷檢測服務,主要包括診斷外包服務及為醫聯體提供的診斷檢測服務,亦向非醫療機構提供少量診斷檢測服務。 |
| Listing Date | 2022-05-18 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國廣州市黃埔區科學城荔枝山路6號 |
| Business Address (Hong Kong) | 香港銅鑼灣希慎道33號利園一期19樓1901室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | yunkanghealth.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 7.89 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 3,945 |
| Par Value | To be extracted |
| Offer Period | 2022-05-05 to 2022-05-11 |
| Global Offering Shares | 138,188,000 shares |
| HK Public Offer Shares (Initial) | 13,819,000 shares (10.0%) |
| Public Offer Lots (Initial) | 27,638lots (Pool A13,819lots,Pool B13,819lots) |
| International Placing Shares (Initial) | 124,369,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 613,188,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 27.4% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,090,303,320 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 3,945 |
| 2 lots | 1,000 | HK$ 7,890 |
| 3 lots | 1,500 | HK$ 11,835 |
| 4 lots | 2,000 | HK$ 15,780 |
| 5 lots | 2,500 | HK$ 19,725 |
| 6 lots | 3,000 | HK$ 23,670 |
| 7 lots | 3,500 | HK$ 27,615 |
| 8 lots | 4,000 | HK$ 31,560 |
| 9 lots | 4,500 | HK$ 35,505 |
| 10 lots | 5,000 | HK$ 39,450 |
| 12 lots | 6,000 | HK$ 47,340 |
| 14 lots | 7,000 | HK$ 55,230 |
| 16 lots | 8,000 | HK$ 63,120 |
| 18 lots | 9,000 | HK$ 71,010 |
| 20 lots | 10,000 | HK$ 78,900 |
| 30 lots | 15,000 | HK$ 118,350 |
| 40 lots | 20,000 | HK$ 157,800 |
| 50 lots | 25,000 | HK$ 197,250 |
| 60 lots | 30,000 | HK$ 236,700 |
| 70 lots | 35,000 | HK$ 276,150 |
| 80 lots | 40,000 | HK$ 315,600 |
| 90 lots | 45,000 | HK$ 355,050 |
| 100 lots | 50,000 | HK$ 394,500 |
| 120 lots | 60,000 | HK$ 473,400 |
| 140 lots | 70,000 | HK$ 552,300 |
| 200 lots | 100,000 | HK$ 789,000 |
| 400 lots | 200,000 | HK$ 1,578,000 |
| 600 lots | 300,000 | HK$ 2,367,000 |
| 800 lots | 400,000 | HK$ 3,156,000 |
| 1,000 lots | 500,000 | HK$ 3,945,000 |
| 1,200 lots | 600,000 | HK$ 4,734,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,400 lots | 700,000 | HK$ 5,523,000 |
| 2,000 lots | 1,000,000 | HK$ 7,890,000 |
| 4,000 lots | 2,000,000 | HK$ 15,780,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 411.2M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +2262% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 4,838,053,320 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣381.9百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue | 677,826 | 1,200,320 | 1,696,740 |
| Cost of sales | -378,632 | -544,425 | -797,603 |
| Gross profit | 299,194 | 655,895 | 899,137 |
| Other income and gains, net | 6,115 | 14,056 | 7,869 |
| Selling and distribution expenses | -192,655 | -219,015 | -273,304 |
| Administrative expenses | -112,749 | -104,753 | -152,078 |
| Operating profit | 3,060 | 341,462 | 457,694 |
| Net finance costs | -11,731 | -17,075 | -6,474 |
| Share of associates and JVs | -1,961 | -1,559 | |
| Profit before tax | -10,632 | 322,828 | 451,220 |
| Income tax expense | -757 | -52,519 | -78,722 |
| Profit for the year | -31,544 | 260,172 | 381,893 |
| Profit attributable to owners | -30,957 | 255,334 | 380,932 |
Balance Sheet
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Cash and cash equivalents | 63,955 | 335,835 | 800,695 |
| Trade and bills receivables | 260,405 | 484,514 | 825,301 |
| Inventories | 15,156 | 24,553 | 41,697 |
| Total current assets | 418,552 | 1,387,991 | 1,743,255 |
| Total assets | 1,269,246 | 1,956,731 | 2,455,413 |
| Total current liabilities | 411,973 | 806,665 | 870,838 |
| Total liabilities | 478,839 | 890,347 | 1,003,833 |
| Total equity | 790,407 | 1,066,384 | 1,451,580 |
| Equity attributable to owners | 775,675 | 1,047,908 | 1,451,704 |
| Interest-bearing borrowings | 186,248 | 472,176 | 290,685 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Net cash from operating activities | 4,847 | 203,084 | 369,459 |
| Net cash from investing activities | -322,815 | -191,094 | 310,722 |
| Net cash from financing activities | -18,457 | 260,992 | -215,321 |
| Net increase in cash | -336,425 | 272,982 | 464,860 |
| Purchase of PP&E | -27,370 | -45,334 | -222,918 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 8.5 |
|---|---|
| First Day Open | HK$ 7.89 |
| First Day Change | 7.73% |
| First Day Volume | 31186000.0 |
| First Day Turnover | 237815000.0 |
| Use of Proceeds | 1、約55.0%或418.5百萬港元,將用于未來四年擴大并深化我們醫聯體網絡,主要于華東地區、華中地區及華南地區;
2、約20.0%或152.2百萬港元將于未來三年內分配用于升級并提升我們醫學運營服務提供商的營運能力,以提高營運效率及數字化檢測服務;
3、約10.0%或76.1百萬港元將分配用于擴大我們的診斷能力及豐富我們的診斷檢測組合,于未來三年重點發展關鍵技術的能力;
4、約5.0%或38.0百萬港元將分配用于尋找潛在投資及收購機會;
5、約5.0%或38.0百萬港元將分配用于招聘及培訓人才庫,重點是管理及技術人員;
6、約5.0%或38.0百萬港元將用作我們的營運資金及一般企業用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (6)
Joint Lead Managers (8)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 235,402,095 HKD | — | 21.59% | — | 6 months | 2022-11-18 |
| 2 | 亚辉龙(香港)有限公司 | 62,772,840 HKD | — | 5.76% | — | 6 months | 2022-11-18 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 張勇 | — |
| Company Secretary | 林穎嘉、陳濼而 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 緊隨全球發售完成後,YK Development持有約40.79%權益,達安國際持有約34.21%權益,張勇先生及達安基因等為控股股東。 |
|---|




